Empowering People to be Ambassadors of their Own Health Since 1997.


Weekly News

Weekly news updates are currently posted on the Internet site and sent out via e-blast to provide up-to-date information on what has been covered in the news regarding hepatitis C in the previous week.  Topics include all stories related to hepatitis C  as well as personal stories and events.

HCV News

Week Ending 07/27/2015

Project ECHO: Force Multiplier For Community Health Centers

‘Even with the Affordable Care Act, millions of Americans struggle to access health care when they need it. A huge part of the problem is a lack of both primary care and specialty providers in rural and other underserved communities. Without local providers who can meet patients’ needs, health care coverage does not necessarily translate to access to care.’

Area veteran can’t get treatment for Hepatitis C

‘Adam Shaffer, a disabled veteran with two tours in Iraq, discovered that the Department of Veterans Affairs has a cure for one of the things that ails him. Only thing is: He can’t get it. “With Hepatitis C, the government doesn’t have enough money to give veterans the pills,” said the 30-year-old Shaffer. “They put you on a waiting list, and it’s long. You can’t get any treatment. It will kill you.”’

Georgia launches HCV elimination program with help from CDC

‘In collaboration with the CDC, the country of Georgia launched a hepatitis C virus infection elimination program with the intention of providing and treating people with new curative regimens, providing discounted diagnostics and improving ways for diagnosing and treating the infection in the region, according to a new report.’

FDA Gives Nod to Daklinza —Drug to be used in combination with Sovaldi to treat genotype 3 HCV

‘Another hepatitis C drug won FDA approval: daclatasvir (Daklinza), for patients with difficult-to-treat genotype 3 hepatitis C (HCV). An NS5A replication complex inhibitor, the agent is indicated in combination with sofosbuvir (Sovaldi), which blocks the action of the viral NS5B polymerase. The combination is the first 12-week, all-oral therapy for genotype 3 patients approved in the U.S. Daclatasvir, made by Bristol-Myers Squibb, has already been approved in Europe and elsewhere. Sofosbuvir was approved in the U.S. in 2013.’

Janssen Submits Supplemental New Drug Application to U.S. FDA for All-Oral, Once-Daily OLYSIO® (Simeprevir) in Combination with Sofosbuvir

‘Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to update the label for once-daily, all-oral OLYSIO® (simeprevir).’

FDA approves Technivie for treatment of chronic hepatitis C genotype 4

‘The U.S. Food and Drug Administration today approved Technivie (ombitasvir, paritaprevir and ritonavir) for use in combination with ribavirin for the treatment of hepatitis C virus (HCV) genotype 4 infections in patients without scarring and poor liver function (cirrhosis).’

OSAP to present webinar on the hepatitis C virus this August

‘The Organization for Safety, Asepsis and Prevention (OSAP), the advocate for The Safest Dental Visit, in collaboration with the Centers for Disease Control and Prevention (CDC) and the Academy of General Dentistry (AGD), is presenting a webinar on the hepatitis C virus (HCV) on August 19, 12:00-1:30 p.m. CDT. The goal of the webinar is to bring dental teams up to date with HCV and new HCV therapies. HCV can survive in the environment for 16 hours on a dry surface and can be detected in saliva.’

County lacks up-to-date hepatitis data

‘Data reporting delays appear to be hampering efforts to slow the spread of the Hepatitis C virus (HCV) that is infecting people who share needles to inject drugs. In Delaware County, there were 152 newly reported cases of HCV in 2013 — a rate of 130 cases per 100,000 population, according to the Indiana State Department of Health.’

Caring Ambassadors Program, Inc. | P.O. Box 1748 | Oregon City, OR 97045 | 503-632-9032 | 503-632-9038 (Fax)